Neurology News

The NIH announced that it has launched phase 2 clinical trials that will evaluate potential treatments for long COVID conditions as part of its Researching COVID to Enhance Recovery, or RECOVER, initiative.

Women were more likely than men to leave academic medicine at all career stages, highlighting the need for diversity, equity and inclusion efforts that target recruiting and retaining female physicians, according to an expert.

Rates of adverse events were similar in both the pimavanserin group and placebo group.Pimavanserin was well-tolerated and not associated with cognitive decline or motor dysfunction in older adults with Parkinson’s disease and neuropsychiatric symptoms, according to a poster presentation.

A Bay Area-based precision care company has announced $30 million in funding to continue providing care for those with multiple sclerosis and other neurodegenerative diseases.

New guidance from the American Academy of Neurology on early Alzheimer’s disease treatment calls for greater collaboration from patients, caregivers and clinicians as well as the embrace of new therapeutics.

The FDA has granted breakthrough therapy designation to an investigational antisense nucleotide therapeutic to treat individuals with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.

Aerobic-resistance exercises combined with cognitive training improved cognition compared with exercise alone in older adults with mild cognitive impairment, a recent study found.

The risk for dementia was 2.41 times greater in Danish adults with diagnosed depression, an association that persisted when depression was diagnosed in early and middle life, according to research in JAMA Neurology.

Prevalence of mild cognitive impairment among United States military veterans aged 65 years and older increased from 2010 to 2019, according to a poster presented at the Alzheimer’s Association International Conference.

BOSTON — Initiating treatment with a high-efficacy therapeutic such as ocrelizumab as early as possible is effective for those with multiple sclerosis, according to a presenter at the American Academy of Neurology annual meeting.